ICTA
Michel Hantzperg is the President at INTERNATIONAL CLINICAL TRIALS ASSOCIATION. According to Michel, ICTA has developed most of its clinical studies in Europe and in the United Kingdom and guided the set-up “overseas” of clinical development plans. Indeed, Europe makes it possible to blend proximity and cultural diversity, which is a necessary requirement for the achievement of pre-Marketing Authorization clinical development phases, whatever the mode.